Hannah is a Ph.D. candidate at the University of North Carolina at Chapel Hill, where she conducts her dissertation research in Ben Philpot’s lab. She brings preiovus experience from Ionis Pharmaceuticals, where she worked in high‑throughput screening, and from Design Therapeutics, where she led efforts on the Huntington’s disease program. Her research centers on uncovering genetic regulators of Ube3a expression in primary neurons to support the development of small‑molecules for Angelman syndrome.